Welcome to the second “Payer Perspectives in Dermatology” series. This series will shine a light on the skin condition known as rosacea—an underrecognized and undertreated disorder that is frequently misunderstood. The goal is to update readers about its causes, manifestations, and treatments, including current and emerging therapies. A better understanding of rosacea among the payer community should lead to greater access to effective treatments for patients.
Rosacea is a chronic skin disease that often requires continuous treatment, but data about healthcare utilization and the costs associated with its management have been lacking, especially for relatively newer therapies. James D. Kendall, PharmD, and Norman J. Preston, PhD, of Galderma Laboratories, LP, recently addressed this information gap in a poster presentation at the 2013 Academy of Managed Care Pharmacy Nexus meeting.
Mirvaso (Brimonidine): First Topical Gel Approved by the FDA for the Treatment of Facial Erythema of Rosacea
Rosacea, a chronic and potentially life-disrupting skin condition, affects an estimated 16 million people in the United States.1,2 Although rosacea generally affects the facial area, it can also occur on the neck, ears, scalp, or chest.2 The manifestations of rosacea include facial erythema; visible blood vessels; swollen, red acne-like bumps; dry eyes; and swollen, reddened eyelids.2,3
On August 26, 2013, the US Food and Drug Administration (FDA) approved topical brimonidine gel 0.33% (Mirvaso, Galderma Laboratories) for the treatment of erythema in rosacea in adults aged 18 years and older. This is the first drug approved by the FDA for the treatment of this condition, and it answers an unmet need in addressing the facial erythema that is a hallmark of this skin disorder.
Rosacea is a common skin condition that leads to persistent erythema, transient flushing, and/or acne-like eruptions across the face. Although effective treatments exist for the pimples and pustules associated with rosacea (ie, papulopustular rosacea), the effective relief of erythema in rosacea (ie, erythematotelangiectatic rosacea) is an unmet medical need.
Rosacea is a common and chronic skin disorder with characteristic signs and symptoms, including flushing, facial erythema, inflammatory papules and pustules, telangiectasia, edema, and watery or irritated eyes.1 Four clinical subtypes of rosacea have been characterized, including erythematotelangiectatic, papulopustular, phymatous, and ocular.2 It is common for patients to present with more than 1 subtype.
The Psychosocial Impact of Skin Disorders: Time for a Closer Look?
The skin condition known as rosacea is a common and serious disorder that is underrecognized and undertreated. According to the American Academy of Dermatology, rosacea affects at least 14 million US adults, or 1 in every 10 individuals.1 According to the National Rosacea Society (NRS), that number is now estimated to be 16 million.2 Despite this relatively high incidence, the diagnosis of rosacea is often delayed or is never made.2 The consequence is needless suffering for many patients.
For many patients suffering from rosacea, simple interventions can lessen some of the symptoms. Patients should receive instruction on proper skin care, education about potential triggers, and reassurance that with effective management their skin should improve and the most severe form of rosacea—phymatous changes—will be avoided. When these simple strategies are not sufficient, medications are available to target some components of rosacea, although an effective treatment for the skin redness that is associated with rosacea remains an unmet need.
Page 2 of 3
Results 11 - 20 of 25
Results 11 - 20 of 25